Stay updated on Copanlisib Plus Nivolumab Combo in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Copanlisib Plus Nivolumab Combo in Solid Tumors Clinical Trial page.

Latest updates to the Copanlisib Plus Nivolumab Combo in Solid Tumors Clinical Trial page
- Check6 days agoChange DetectedAdded Squamous cell carcinoma of the head and neck to the study's listed conditions.SummaryDifference0.1%

- Check13 days agoChange DetectedThe revision label on the page was updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check20 days agoChange DetectedAdded Hepatocellular carcinoma to the Conditions section and included the Genetic and Rare Diseases Information Center as a Resources link.SummaryDifference0.2%

- Check28 days agoChange DetectedRevision: v3.4.3 updated from v3.4.2.SummaryDifference0.1%

- Check42 days agoChange DetectedSponsor-related navigation text and links referencing Bayer were removed from the study page.SummaryDifference0.2%

- Check49 days agoChange DetectedRevision tag changed from v3.4.1 to v3.4.2 with no visible content or functional changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Copanlisib Plus Nivolumab Combo in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Copanlisib Plus Nivolumab Combo in Solid Tumors Clinical Trial page.